Coherus BioSciences to divest YUSIMRY in $40m deal

Coherus BioSciences has agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial (HKF) for up-front all-cash consideration of $40 million.

YUSIMRY is a multi-indication biosimilar to AbbVie’s HUMIRA (adalimumab). YUSIMRY is indicated for use across multiple rheumatologic, gastroenterologic, and dermatologic indications, including: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Colitis, Plaque Psoriasis, Hidradenitis Suppurativa.

Meitheal Pharmaceuticals, a wholly owned subsidiary of HKF, will continue to commercialize YUSIMRY in the U.S.

“With the divesture of YUSIMRY, Coherus reinforces its strategic focus on oncology,” said Denny Lanfear, Coherus Chairman and Chief Executive Officer. “The proceeds from the sale of YUSIMRY will bolster our cash position, advance our efforts to become a sustainable and growing oncology company and efficiently allocate our resources for maximum value creation.”

Coherus’ oncology assets include LOQTORZI (toripalimab-tpzi), an FDA-approved, next-generation PD-1 inhibitor, the UDENYCA (pegfilgrastim-cbqv) franchise, with three FDA-approved presentations; and an innovative clinical-stage, immuno-oncology portfolio focused on the tumor microenvironment.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news